{"title":"新辅助肝动脉灌注化疗改善肝细胞癌手术预后的潜力：一项系统回顾和荟萃分析。","authors":"Zi-Kui Shang, Jian-Hua Zhang, Jia-Hai Zhu, Chuan-Sen Deng, Xi-Yuan Chen, Ran-Xia, Chun-Quan Sun","doi":"10.1186/s12957-025-03859-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to assess the effectiveness of adjuvant treatment with new hepatic arterial infusion chemotherapy (HAIC) prior to hepatic resection in patients with resectable hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A systematic review was conducted utilizing established databases and registries as of January 15, 2025, without imposing restrictions based on language, publication date, or status. The inclusion criteria were met by studies that examined the effects of HAlC, with or without surgical intervention, in comparison to surgical treatment alone. The primary outcomes encompassed overall survival (OS) and disease-free survival (DFS), while secondary outcomes included recurrence rate and adverse events. A random effects model was employed to analyze the data.</p><p><strong>Results: </strong>A total of 10 studies involving 1,014 patients were included. The results showed that preoperative HAlC improved patient survival (OS), disease-free survival (DFS), and recurrence rates compared with surgical treatment alone. The most common grade 3 and higher adverse reactions in patients treated with preoperative HAIC included vomiting, leukopenia, neutropenia, hypothyroidism, and diarrhea.</p><p><strong>Conclusion: </strong>Preoperative HAIC has been demonstrated to enhance survival outcomes in patients with resectable HCC; however, the clinical efficacy of this approach requires further validation through large-scale design studies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"207"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123804/pdf/","citationCount":"0","resultStr":"{\"title\":\"Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.\",\"authors\":\"Zi-Kui Shang, Jian-Hua Zhang, Jia-Hai Zhu, Chuan-Sen Deng, Xi-Yuan Chen, Ran-Xia, Chun-Quan Sun\",\"doi\":\"10.1186/s12957-025-03859-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The purpose of this study was to assess the effectiveness of adjuvant treatment with new hepatic arterial infusion chemotherapy (HAIC) prior to hepatic resection in patients with resectable hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A systematic review was conducted utilizing established databases and registries as of January 15, 2025, without imposing restrictions based on language, publication date, or status. The inclusion criteria were met by studies that examined the effects of HAlC, with or without surgical intervention, in comparison to surgical treatment alone. The primary outcomes encompassed overall survival (OS) and disease-free survival (DFS), while secondary outcomes included recurrence rate and adverse events. A random effects model was employed to analyze the data.</p><p><strong>Results: </strong>A total of 10 studies involving 1,014 patients were included. The results showed that preoperative HAlC improved patient survival (OS), disease-free survival (DFS), and recurrence rates compared with surgical treatment alone. The most common grade 3 and higher adverse reactions in patients treated with preoperative HAIC included vomiting, leukopenia, neutropenia, hypothyroidism, and diarrhea.</p><p><strong>Conclusion: </strong>Preoperative HAIC has been demonstrated to enhance survival outcomes in patients with resectable HCC; however, the clinical efficacy of this approach requires further validation through large-scale design studies.</p>\",\"PeriodicalId\":23856,\"journal\":{\"name\":\"World Journal of Surgical Oncology\",\"volume\":\"23 1\",\"pages\":\"207\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123804/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12957-025-03859-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03859-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.
Background: The purpose of this study was to assess the effectiveness of adjuvant treatment with new hepatic arterial infusion chemotherapy (HAIC) prior to hepatic resection in patients with resectable hepatocellular carcinoma (HCC).
Methods: A systematic review was conducted utilizing established databases and registries as of January 15, 2025, without imposing restrictions based on language, publication date, or status. The inclusion criteria were met by studies that examined the effects of HAlC, with or without surgical intervention, in comparison to surgical treatment alone. The primary outcomes encompassed overall survival (OS) and disease-free survival (DFS), while secondary outcomes included recurrence rate and adverse events. A random effects model was employed to analyze the data.
Results: A total of 10 studies involving 1,014 patients were included. The results showed that preoperative HAlC improved patient survival (OS), disease-free survival (DFS), and recurrence rates compared with surgical treatment alone. The most common grade 3 and higher adverse reactions in patients treated with preoperative HAIC included vomiting, leukopenia, neutropenia, hypothyroidism, and diarrhea.
Conclusion: Preoperative HAIC has been demonstrated to enhance survival outcomes in patients with resectable HCC; however, the clinical efficacy of this approach requires further validation through large-scale design studies.
期刊介绍：
World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics.
Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
